Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Jieyu Capsules in the Treatment of Depression
NCT07785284Not yet recruiting
- Sponsor
- Peking University
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of Shugan Jieyu in major depressive disorder (MDD), sponsored by Peking University. Primary endpoint: Total effective rate based on Hamilton Depression Scale-17 score at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07785284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785284.